Premium
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA
Author(s) -
Spriano F.,
Chung E.,
Napoli S.,
Tarantelli C.,
Gaudio E.,
Cascione L.,
Cavalli A.,
Rinaldi A.,
Kwee I.,
Ye H.,
Rossi D.,
Zucca E.,
Stathis A.,
Jessen K.,
Lannutti B.,
Toretsky J.,
Bertoni F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.132_2630
Subject(s) - lenalidomide , cancer research , ibrutinib , venetoclax , irf4 , in vivo , lymphoma , chemistry , medicine , transcription factor , multiple myeloma , biology , immunology , leukemia , chronic lymphocytic leukemia , biochemistry , microbiology and biotechnology , gene